Sep 30, 2026 —
Researchers at Aarhus University have used prime editing to correct the genetic defect behind GATA2 deficiency in patients’ own blood stem cells, a preclinical proof of concept published in Science Translational Medicine. GATA2 deficiency is a severe inherited immunodeficiency that leaves patients short of immune cells and prone to serious infections and blood cancers.
Working in patient-derived CD34+ hematopoietic stem and progenitor cells, the team corrected a specific GATA2 variant using prime editing, an approach that rewrites DNA without cutting both strands. They reached up to 70% editing efficiency and raised the share of functional gene copies from 50% to 77%, with limited on-target genotoxicity and no detectable off-target edits at the top 20 predicted sites.
The corrected stem cells also engrafted better than untreated cells, and a short prestimulation step preserved their stemness while limiting p53 activation. The group described a companion technique, PASSIGE, for inserting larger DNA sequences without a double-strand break, which could cover a broader range of GATA2 mutations. The work is preclinical, in patient-derived cells; no patient has been treated.
